286 related articles for article (PubMed ID: 10519604)
1. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
Barnes SD; Campagna JA; Dirks MS; Doe EA
Ophthalmology; 1999 Oct; 106(10):2033-7. PubMed ID: 10519604
[TBL] [Abstract][Full Text] [Related]
2. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
4. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
Yuen NS; Cheung P; Hui SP
Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of apraclonidine 1% versus pilocarpine 4% for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty.
Ren J; Shin DH; Chung HS; Birt CM; Glover BK; Juzych MS; Hughes BA; Kim C
Ophthalmology; 1999 Jun; 106(6):1135-9. PubMed ID: 10366082
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
7. Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. The Brimonidine-ALT Study Group.
Ophthalmic Surg Lasers; 1995; 26(5):404-9. PubMed ID: 8963853
[TBL] [Abstract][Full Text] [Related]
8. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
[TBL] [Abstract][Full Text] [Related]
9. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Nishimoto JH; Chang FW; Tang IH; Kolin T
J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
[TBL] [Abstract][Full Text] [Related]
10. Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty.
Threlkeld AB; Assalian AA; Allingham RR; Shields MB
Ophthalmic Surg Lasers; 1996 Aug; 27(8):657-60. PubMed ID: 8858630
[TBL] [Abstract][Full Text] [Related]
11. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine.
Lewis R; Perkins TW; Gangnon R; Kaufman PL; Heatley GA
Ophthalmology; 1998 Dec; 105(12):2256-9. PubMed ID: 9855156
[TBL] [Abstract][Full Text] [Related]
12. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Unal M; Yücel I; Akar Y
J Cataract Refract Surg; 2006 Sep; 32(9):1499-502. PubMed ID: 16931262
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
14. Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty.
Robin AL
Ophthalmic Surg; 1991 Jan; 22(1):31-7. PubMed ID: 2014108
[TBL] [Abstract][Full Text] [Related]
15. Early intraocular pressure response to laser trabeculoplasty 180 degrees without apraclonidine versus 360 degrees with apraclonidine.
Allf BE; Shields MB
Ophthalmic Surg; 1991 Sep; 22(9):539-42. PubMed ID: 1682861
[TBL] [Abstract][Full Text] [Related]
16. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes.
Chung HS; Shin DH; Birt CM; Kim C; Lee D; Levin DS; Hakimzadeh R; Juzych MS
Ophthalmology; 1997 Nov; 104(11):1921-5. PubMed ID: 9373127
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
thoe Schwartzenberg GW; Buys YM
Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
[TBL] [Abstract][Full Text] [Related]
18. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
Ma YR; Lee BH; Yang KJ; Park YG
Korean J Ophthalmol; 1999 Dec; 13(2):78-84. PubMed ID: 10761402
[TBL] [Abstract][Full Text] [Related]
20. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
Seong GJ; Lee YG; Lee JH; Lim SJ; Lee SC; Hong YJ; Kwon OW; Kim HB
Ophthalmic Surg Lasers; 2000; 31(4):308-14. PubMed ID: 10928668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
